Youn Hee Jee1, Francesco S Celi2, Maureen Sampson3, David B Sacks3, Alan T Remaley3, Electron Kebebew4, Jeffrey Baron1. 1. Section on Growth and Development, Program on Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. 2. Division of Endocrinology and Metabolism, Virginia Commonwealth University, Bethesda, MD, USA. 3. Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA. 4. Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract
CONTEXT: The primary preoperative method for distinguishing malignant from benign thyroid nodules is fine-needle aspiration (FNA) cytology, but it is frequently inconclusive. Midkine (MDK) is a heparin-binding growth factor, which is overexpressed in papillary thyroid carcinoma (PTC). OBJECTIVE: We measured MDK concentrations in FNA samples from benign and malignant thyroid nodules to explore the possibility that MDK measurement might aid in the evaluation of thyroid nodules. DESIGN: 35 subjects underwent preoperative FNA of 45 thyroid nodules, followed by thyroidectomy, providing a histological diagnosis. FNA needle contents were first expressed for cytology, and then, the needle was washed with buffer for immunoassay. In 46 subjects without preoperative FNA samples, FNA was performed ex vivo on 62 nodules within surgically excised thyroid tissue. MEASUREMENTS: MDK was measured using a high-sensitivity sandwich ELISA and normalized to thyroglobulin (Tg) concentration in the sample to adjust for tissue content in the aspirate. RESULTS: The MDK/Tg ratio was higher in 18 PTCs than in 87 benign nodules (204 ± 106 vs 1·2 ± 0·3 ng/mg, mean ± SEM, P < 0·001). Using a threshold of 10 ng/mg, the sensitivity and specificity of the MDK/Tg ratio for diagnosis of PTC were 67% and 99%, respectively. All follicular variant PTCs had a MDK/Tg ratio <10 ng/mg. CONCLUSIONS: The findings indicate that, in FNA samples, the MDK/Tg ratio in PTC is greater than in benign thyroid nodules, raising the possibility that this approach might provide adjunctive diagnostic or prognostic information to complement existing approaches. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
CONTEXT: The primary preoperative method for distinguishing malignant from benign thyroid nodules is fine-needle aspiration (FNA) cytology, but it is frequently inconclusive. Midkine (MDK) is a heparin-binding growth factor, which is overexpressed in papillary thyroid carcinoma (PTC). OBJECTIVE: We measured MDK concentrations in FNA samples from benign and malignant thyroid nodules to explore the possibility that MDK measurement might aid in the evaluation of thyroid nodules. DESIGN: 35 subjects underwent preoperative FNA of 45 thyroid nodules, followed by thyroidectomy, providing a histological diagnosis. FNA needle contents were first expressed for cytology, and then, the needle was washed with buffer for immunoassay. In 46 subjects without preoperative FNA samples, FNA was performed ex vivo on 62 nodules within surgically excised thyroid tissue. MEASUREMENTS: MDK was measured using a high-sensitivity sandwich ELISA and normalized to thyroglobulin (Tg) concentration in the sample to adjust for tissue content in the aspirate. RESULTS: The MDK/Tg ratio was higher in 18 PTCs than in 87 benign nodules (204 ± 106 vs 1·2 ± 0·3 ng/mg, mean ± SEM, P < 0·001). Using a threshold of 10 ng/mg, the sensitivity and specificity of the MDK/Tg ratio for diagnosis of PTC were 67% and 99%, respectively. All follicular variant PTCs had a MDK/Tg ratio <10 ng/mg. CONCLUSIONS: The findings indicate that, in FNA samples, the MDK/Tg ratio in PTC is greater than in benign thyroid nodules, raising the possibility that this approach might provide adjunctive diagnostic or prognostic information to complement existing approaches. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
Authors: A Bergenfelz; S Jansson; A Kristoffersson; H Mårtensson; E Reihnér; G Wallin; I Lausen Journal: Langenbecks Arch Surg Date: 2008-07-17 Impact factor: 3.445
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Erik K Alexander; Giulia C Kennedy; Zubair W Baloch; Edmund S Cibas; Darya Chudova; James Diggans; Lyssa Friedman; Richard T Kloos; Virginia A LiVolsi; Susan J Mandel; Stephen S Raab; Juan Rosai; David L Steward; P Sean Walsh; Jonathan I Wilde; Martha A Zeiger; Richard B Lanman; Bryan R Haugen Journal: N Engl J Med Date: 2012-06-25 Impact factor: 91.245
Authors: P S de Matos; A P Ferreira; F de Oliveira Facuri; L V M Assumpção; K Metze; L S Ward Journal: Histopathology Date: 2005-10 Impact factor: 5.087
Authors: Hossein Gharib; Enrico Papini; Roberto Valcavi; H Jack Baskin; Anna Crescenzi; Massimo E Dottorini; Daniel S Duick; Rinaldo Guglielmi; Carlos Robert Hamilton; Martha A Zeiger; Michele Zini Journal: Endocr Pract Date: 2006 Jan-Feb Impact factor: 3.443
Authors: E Saggiorato; R De Pompa; M Volante; S Cappia; F Arecco; A P Dei Tos; F Orlandi; M Papotti Journal: Endocr Relat Cancer Date: 2005-06 Impact factor: 5.678
Authors: Mark G Shrime; David P Goldstein; Raewyn M Seaberg; Anna M Sawka; Lorne Rotstein; Jeremy L Freeman; Patrick J Gullane Journal: Arch Otolaryngol Head Neck Surg Date: 2007-12
Authors: Youn Hee Jee; Samira M Sadowski; Francesco S Celi; Liqiang Xi; Mark Raffeld; David B Sacks; Alan T Remaley; Anton Wellstein; Electron Kebebew; Jeffrey Baron Journal: PLoS One Date: 2016-02-25 Impact factor: 3.240
Authors: Youn Hee Jee; Kun Song Lee; Shanna Yue; Ellen W Leschek; Matthew G Boden; Aysha Jadra; Anne Klibanski; Priya Vaidyanathan; Madhusmita Misra; Young Pyo Chang; Jack A Yanovski; Jeffrey Baron Journal: PLoS One Date: 2019-10-24 Impact factor: 3.240